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ABSTRACT 64 
Background & Aims  65 
Intestinal failure (IF) is defined from a requirement or intravenous supplementation due to failing 66 
capacity to absorb nutrients and fluids. Acute IF is an acute, potentially reversible form of IF. We 67 
aimed to identify the prevalence, underlying causes and outcomes of acute IF. 68 
Methods 69 
This point-of-prevalence study included all adult patients hospitalized in acute care hospitals and 70 
receiving parenteral nutrition (PN) on a study day. The reason for PN and the mechanism of IF (if 71 
present) were documented by local investigators and reviewed by an expert panel. 72 
Results 73 
Twenty-three hospitals (19 university, 4 regional) with a total capacity of 16,356 acute care beds and 74 
1,237 intensive care unit (ICU) beds participated in this study. On the study day, 338 patients 75 
received PN (21 patients/1000 acute care beds) and 206 (13/1000) were categorized as acute IF. The 76 
categorization of reason for PN was revised in 64 cases (18.9% of total) in consensus between the 77 
expert panel and investigators. Hospital mortality of all study patients was 21.5%; the median 78 
hospital stay was 36 days.  Patients with acute IF had a hospital mortality of 20.5% and median 79 
hospital stay of 38 days (P>0.05 for both outcomes).  Disordered gut motility (e.g. ileus) was the most 80 
common mechanism of acute IF, and 71.5% of patients with acute IF had undergone abdominal 81 
surgery. Duration of PN of ≥42 days was identified as being the best cut-off predicting hospital 82 
mortality within 90 days. PN ≥42 days was independently associated with 90-day hospital mortality, 83 
age, sepsis, and ICU admission. 84 
Conclusions 85 
Around 2% of adult patients in acute care hospitals received PN, 60% of them due to acute IF. High 86 
90-day hospital mortality and long hospital stay were observed in patients receiving PN, whereas 87 
presence of acute IF did not additionally influence these outcomes. Duration of PN was associated 88 
with increased 90-day hospital mortality.   89 
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INTRODUCTION 90 
A definition of intestinal failure (IF) was first proposed in 1981 by Fleming and Remington (1). 91 
Recently, the European Society for Clinical Nutrition and Metabolism (ESPEN) proposed the following 92 
definition: the reduction of gut function below the minimum necessary for the absorption of 93 
macronutrients and/or water and electrolytes, such that intravenous supplementation (IVS) is 94 
required to maintain health and/or growth (2,3). Along with this definition, three types of IF are 95 
described: types I to III IF. Type I acute IF (AIF) is an acute, short-term and usually self-limiting 96 
condition, commonly occurring in the perioperative setting and/or in association with critical 97 
illnesses, and requiring IVS from a few days to a few weeks. Type II AIF is a prolonged acute 98 
condition, often in metabolically unstable patients such as those with complicated intra-abdominal 99 
infection or acute mesenteric ischemia, often needing multiple surgeries and/or developing 100 
enterocutaneous fistulae, requiring complex multi-disciplinary care and IVS over periods of weeks or 101 
months. Type III IF (chronic IF = CIF) is a chronic condition, in metabolically stable patients, who 102 
require IVS over months or years.  103 
Since the first definition, further reviews and studies have analyzed the causes, outcomes and quality 104 
of life in chronic IF (4,5,6,7). One recent paper describes the underlying pathologies causing acute IF 105 
and the outcome of patients with acute IF (8). However, the actual prevalence of acute IF is still 106 
unknown. Based on data from the National Health Service (NHS) in the United Kingdom, the annual 107 
incidence of type II IF has been estimated to be around 9-18 patients per million inhabitants, 108 
depending on the method used (9).  It has been estimated that about 50% of type II IF may develop 109 
into type III IF (3). 110 
The etiology of acute IF has also not been studied in detail. The most likely underlying conditions for 111 
acute IF are perioperative complications, or those associated with critical illness, such as bowel 112 
paralysis or acute pancreatitis (5). 113 
This study was conducted: 1) to identify the prevalence of acute IF; 2) to identify the mechanisms 114 
and diseases underlying IF; 3) to describe the 90 day outcome for patients with acute IF. 115 
 116 
  117 
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MATERIALS AND METHODS 118 
Study design 119 
This was a multicenter point-of-prevalence study amongst acute care hospitals worldwide. 120 
There were two points of data collection: 1) study day (a weekday between November 2016 and 121 
March 2017 defined by each hospital); 2) outcome day 90 days after the study day. 122 
Data was collected regarding the category of the hospital (university, regional, local), total numbers 123 
of acute care beds (excluding psychiatric beds) for adult patients in the hospital, as well as the 124 
number of beds in intensive care units (ICU), in specialist IF units and in intermediate care/high-125 
dependency unit(s) (IMC/HDU) if applicable. 126 
All patients receiving PN on the study day independent of their location (ward) in the acute care 127 
hospital were identified and included in the study. The following variables were collected on the 128 
study day: 1) admission variables (age, gender, reason for admission, location in the hospital); 2) data 129 
on PN (the reason for PN, method of administration, total or supplemental PN) and 3) data on IF 130 
(mechanism leading to IF, underlying disease/condition, abdominal surgeries, details of stomas and 131 
fistulas if present).  132 
On the outcome day, the following variables were collected: hospital survival, discharge destination, 133 
total number of days on PN, total number of abdominal surgeries, presence of fistula and stoma at 134 
discharge and total duration of ICU and hospital stay. 135 
Objectives 136 
The primary objective was to identify the prevalence of acute IF among patients treated in acute care 137 
hospitals.  138 
Secondary objectives were to identify prevalence, indications and duration of PN, mechanisms and 139 
outcome of IF, and to compare the hospital length of stay and 90-day hospital mortality of patients 140 
with and without acute IF.  141 
Definitions 142 
Parenteral nutrition was defined as IVS of macronutrients (glucose, amino acids, lipids). 143 
Administration of only glucose solutions in low concentration (<10%), only electrolytes or only 144 
isolated amino acids were not considered as PN in this context. 145 
Intestinal failure was defined based on investigators’ judgment using the definition provided by 146 
ESPEN (2,3). Investigators were asked to separate acute (Type I or II, or not differentiated) and 147 
chronic IF (Type III).  148 
Categorization for pathophysiological mechanisms and underlying diseases of AIF was provided to 149 
investigators (10). Disordered motility was used as an all-encompassing term for impaired motility in 150 
any level of GI tract. 151 
Sepsis was defined as a life-threatening organ dysfunction caused by a dysregulated host response to 152 
infection, according the definition of Singer et al. (11). Septic shock was defined as a clinical construct 153 
of sepsis with persisting hypotension requiring vasopressors to maintain mean arterial blood 154 
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pressure (MAP) ≥65mmHg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate 155 
volume resuscitation (11). 156 
 157 
Data collection and review  158 
Data were collected by local investigators at the individual sites and entered into a web-based 159 
electronic file in de-identified form. 160 
The experts (from the ESPEN Acute Intestinal Failure Special Interest Group (AIF-SIG) reviewed all 161 
cases. Two experts independently performed the review of collected data and suggested changes on 162 
the reasons for PN, and the pathophysiological mechanism and underlying disease/condition for 163 
acute IF when appropriate. Cases where the two experts had different opinions were reviewed 164 
during the AIF-SIG Winter meeting in January 2018. After the AIF-SIG members agreed on the 165 
possible need to change the initial categorizations, queries were sent to the respective local 166 
investigators with a request to review the cases and agree or not with changes suggested by the 167 
experts. 168 
Statistics 169 
IBM Statistics SPSS version 25.0 was used for data analysis.  170 
Data are presented as number of patients (percentage) and median [interquartile range] if not stated 171 
otherwise. The Shapiro-Wilk test was used to test normality of distribution. To compare groups, 172 
Student’s t-test (normal distribution) and Mann-Whitney U test (non-Gaussian distribution) were 173 
used for continuous variables and the Chi-square test for categorical variables. 174 
ROC curve analysis was used to identify the cut-off for duration of PN in predicting 90-day hospital 175 
mortality. 176 
The variables with P≤0.2 on bivariate analysis were tested in stepwise multiple regression analysis for 177 
associations with hospital mortality within 90 days. Competing variables (e.g. total number of ICU 178 
days vs. ICU admission ever) were added and removed stepwise. The final model represents the best 179 
prediction of 90-day hospital mortality with collected data. 180 
Ethics 181 
Ethical approval was obtained by all participating hospitals. Waiver of informed consent was granted. 182 
  183 
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RESULTS 184 
Participating hospitals 185 
A total of 25 sites (in 17 countries) participated in this study (Table 1). Two sites were excluded from 186 
analysis due to failure to include all patients in the whole hospital receiving PN on the study day. Of 187 
the remaining 23 sites, 19 were university hospitals and 4 were regional hospitals. In total, these 188 
hospitals had a capacity of 16,356 acute care beds and 1237 ICU beds. Fifteen hospitals had an IMCU 189 
or HDCU, with a total of 447 beds. Seven hospitals had a specialist IF unit, with a total of 49 beds. 190 
One site was a small hospital specializing only in abdominal surgery (Site number 10 in Table 1). 191 
Table 1. Overview of study sites 192 
Site  Type of 
hospital 
Acute 
care 
beds 
ICU 
beds 
IMC/ 
HDU 
beds 
Specialist 
IF unit 
beds 
Patients 
on PN 
Patients 
with AIF  
Patients 
with CIF  
1 University 876 40 61 0 13 (1.5) 8 (0.9) 0 
2 University 1200 28 15 10    
3 University 745 28 0 10 22 (3.0) 9 (1.2) 6 (0.8) 
4 University 900 180 0 0 21 (2.3) 17 (1.9) 1 (0.1) 
5 University 948 18 10 0 5 (0.5) 3 (0.3) 0 
6 University 508 27 33 0 11 (2.2) 9 (1.8) 2 (0.4) 
7 University 227 5 12 0 3 (1.3) 3 (1.3) 0 
8 University 300 10 8 2 2 (0.7) 2 (0.7) 0 
9 University 1000 52 0 2 4 (0.4) 1 (0.1) 0 
10 Regional 21 4 0 4 6 (28.6) 2 (9.5) 4 (19.0) 
11 Regional 350 10 0 0 5 (1.4) 4 (1.1) 0 
12 University 1200 50 20 0 19 (1.6) 10 (0.8) 3 (0.3) 
13 University 960 21 0 20    
14 University 387 85 49 0 10 (2.6) 7 (1.8) 3 (0.8) 
15 Regional 529 45 133 0 10 (1.9) 5 (0.9) 2 (0.4) 
16 University 762 114 12 0 25 (3.3) 13 (1.7) 5 (0.7) 
17 University 933 50 30 0 17 (1.8) 11 (1.2) 0 
18 Regional 523 19 0 0 7 (1.3) 6 (1.1) 0 
19 University 1142 228 0 0 44 (3.9) 24 (2.1) 17 (1.5) 
20 University 342 18 17 0 13 (3.8) 11 (3.2) 1 (0.3) 
21 University 745 50 28 2 14 (1.9) 13 (1.7) 0 
22 University 1346 93 24 2 41 (3.0) 20 (1.5) 2 (0.1) 
23 University 1127 38 0 0 23 (2.0) 13 (1.2) 3 (0.3) 
24 University 648 27 0 27 13 (2.0) 9 (1.4) 0 
25 University 797 46 10 0 10 (1.3) 6 (0.8) 0 
TOTAL 16’356 1237 447 49 338 (2.1) 206 (1.3) 49 (0.3) 
CI 95% for prevalence   1.58-2.53 1.00 - 1.61 0.11 - 0.41 
TOTAL without 
Site 10 
16’335 1233 447 45 332 (2.0) 204 (1.2) 45 (0.3) 
CI 95% for prevalence without Site 10  1.55 - 2.41 0.99 - 1.58 0.11 - 0.37 
ICU – intensive care unit; IMC/HDU – intermediate care/high-dependency unit; IF – intestinal failure; PN – parenteral 193 
nutrition; AIF –acute intestinal failure; CIF – chronic intestinal failure; CI – confidence interval 194 
 195 
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Data on study day 196 
On the study day, 338 patients received parenteral nutrition (21/1000 acute care beds). One site (Site 197 
number 10 in Table 1) reported a very high prevalence of PN and AIF compared to the others. 198 
Therefore, total prevalence was also recalculated without this site and was 20/1000 acute care beds. 199 
The characteristics of patients receiving PN are presented in Table 2. 200 
In 253/338 (74.9%) patients PN was the only route for administration of nutrients. In patients with 201 
supplemental PN (25.1%) the amount of energy intake through PN varied between 10% and 90% of 202 
total energy intake, with a median of 60%.  203 
Table 2. Characteristics of all patients with PN. Data presented as number of patients (percentage) or median [interquartile 204 
range] if not stated otherwise. 205 
 All patients 
N=338 
CIF 
N=49 
AIF 
N=206 
Non-IF 
N=83 
p-value 
AIF vs 
non-IF 
Male 170 15 114 56 0.021 
Age, median [range] 64 [19-85] 54 [20-83] 63 [19-92] 66 [25-94] 0.081 
Hospital unit     <0.001 
Surgical ward 109 20 (40.8%) 71 (34.5%) 18 (21.7%)  
ICU 102 6 (12.2%) 70 (34.0%) 26 (31.3%)  
Gastroenterology ward 24 5 (10.2%) 13 (6.3%) 6 (7.2%)  
IMC/HDU 22 1 (2.0%) 14 (6.8%) 7 (8.4%)  
Specialized IF Unit 5 4 (8.2%) 1 (0.5%) 0  
Any other acute care ward 
Oncology ward 
Hematology ward 
Transplant unit 
76 
12 
9 
9 
13 (26.5%) 
  1 (2.0%) 
  0 
  6 (12.2%) 
37 (18.0%) 
  4 (1.9%) 
  6 (2.9%) 
  2 (1.0%) 
26 (31.3%) 
  7 (8.4%) 
  3 (3.6%) 
  1 (1.2%) 
 
 
Days on PN before study day 
during current hospitalization 
9 [3-21] 19 [7-71] 8 [3-16] 9 [3-20] 0.949 
Days of hospitalization before 
study day 
16 [8-33] 15 [7-37] 16 [9-33] 16 [10-32] 0.815 
Admission diagnosis category     <0.001 
Gastrointestinal pathology 225 43 (87.7%) 145 (70.4%) 37 (44.6%)   
Cardiac pathology 24 2 (4.1%) 10 (4.9%) 12 (14.5%)  
Pulmonary pathology 20 - 10 (4.9%) 10 (12%)  
Neurological pathology 11 - 2 (1.0%) 9 (10.8%)  
Trauma 3 1 (2.0%) 1 (0.5%) 1 (1.2%)  
Other 55 3 (6.1%) 38 (18.4%) 14 (16.9%)  
Venous access for PN
†     <0.001 
Multi-lumen CVC 144 3 (6.1%) 100 (48.5%) 41 (49.4%)  
Multi-lumen PICC 68 13 (26.5%) 43 (20.9%) 12 (14.5%)  
Tunneled CVC 42 23 (46.9%) 18 (8.7%) 1 (1.2%)  
Single-lumen CVC 29 1 (2.0%) 19 (9.2%) 9 (10.8%)  
Single-lumen PICC 28 7 (14.3%) 13 (6.3%) 8 (9.6%)  
Peripheral 18 1 (2.0%) 8 (3.9%) 9 (10.8%)  
Not sure/other 9 1 (2.0%) 5 (2.4%) 3 (3.6%)  
ICU – intensive care unit; IMC/HDU – intermediate care/high-dependency unit; IF – intestinal failure; PN – parenteral 206 
nutrition; AIF –acute intestinal failure; CIF – chronic intestinal failure; CVC - central venous catheter, PICC - peripherally 207 
inserted central catheter 208 
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Originally, 159 patients were categorized as AIF patients. During case-by-case evaluation of data, 209 
experts suggested and investigators agreed to correct the reason for PN in 64 cases (18.9%). 210 
Corrections were performed in 51/236 of patients (21%) enrolled from study sites without 211 
specialized IF unit and in 13/102 (13%) of patients hospitalized in sites having an IF unit. Reasons for 212 
PN (primarily documented and after revision by expert panel) are presented in Table 3.  213 
Acute IF was primarily documented as a reason for PN in 159 patients; after expert review and re-214 
evaluation by local investigators 206 patients were categorized as acute IF.  This gives a prevalence of 215 
acute IF of 13/1000 acute care beds (12/1000 beds with site number 10 excluded). 216 
Table 3. Reasons for PN, original data and expert revision 217 
 Original data Expert Revision 
 Number % Number % 
Acute IF 159 47.0 206 60.9 
Chronic IF 56 16.6 49 14.5 
No access for EN 25 7.4 27 8.0 
Perceived danger from EN 22 6.5 21 6.2 
Dysphagia 14 4.1 13 3.8 
Severe condition 20 5.9 6 1.8 
Other 35 10.4 16 4.7 
Not sure 7 2.1 - - 
TOTAL 338 100 338 100 
IF – intestinal failure;
 
EN: enteral nutrition 218 
During case-by-case evaluation of the data, experts suggested and investigators agreed to correct the 219 
pathophysiological mechanisms of IF in 17 cases (6.7% of total revised 255 cases of IF); 15 of them 220 
were enrolled from sites without a specialized IF unit. The underlying disease was corrected in 22 221 
cases (8.6%), 18 of them from sites without an IF unit. For all further analyses, corrected 222 
categorizations were used and respective results are presented in Table 4.  223 
Table 4. Pathophysiology and underlying diseases in AIF 224 
 Number of patients 
N=206 
% 
Mechanism of AIF   
Disordered motility 106 51.5 
Obstruction 29 14.1 
Fistula 23 11.2 
Short bowel 12 5.8 
Extensive mucosal disease 12 5.8 
Other 24 11.7 
Underlying disease   
Surgical complication 76 36.9 
Active malignancy 31 15.0 
Crohn’s disease/IBD 16 7.8 
Shock 10 4.9 
Pancreatitis 10 4.9 
Mesenteric vascular pathology 8 3.9 
Primary motility disorder 2 1.0 
Other abdominal pathology 23 11.2 
Other pathology 30 14.6 
AIF – acute intestinal failure; IBD - inflammatory bowel disease 225 
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Of the 106 patients where the mechanism of AIF was considered to be disordered motility, 53 226 
patients had AIF due to a surgical complication, 9 active malignancy, 8 pancreatitis, 6 shock, 3 227 
Crohn’s/inflammatory bowel disease, 1 mesenteric vascular pathology, 1 primary motility disorder, 228 
10 other abdominal pathology (including e.g. cholecystitis/cholangitis, adhesions, abdominal 229 
trauma), and 15 other pathology not of primarily abdominal origin. This other pathology was mainly 230 
hematological malignancy, graft versus host disease or multiple organ failure, resulting in paralytic 231 
ileus or enterocolitis in ICU or IMC/HDU patients (11/15).   232 
In the 24 patients where the mechanism underlying AIF was not considered to be a defined 233 
gastrointestinal problem or dysmotility, the pathophysiological mechanisms of AIF included four 234 
cases of suspected or confirmed bowel ischemia.  The remaining 20 patients had graft versus host 235 
reactions, pancreatitis, peritonitis or recent GI surgery.  On balance the most probable mechanism in 236 
these cases was disordered motility, however, extensive mucosal injury and fear of development or 237 
worsening of AIF due to the administration of EN could not be excluded from the data collected. 238 
Surgical data on 9 patients of the total of 206 patients with AIF were missing.  239 
Of the remaining 197 patients with AIF, 134 patients (68%) had undergone abdominal surgery before 240 
the study day, most patients had undergone a lower (49%) or upper (26%) gastrointestinal (GI tract 241 
procedure. Elective surgery was performed in 85 patients, semi-elective surgery (e.g. change of VAC-242 
dressing) in 25 patients, and emergency surgery in 77 patients. A total of 55 patients had more than 243 
one surgery.  244 
A total of 54 patients had sepsis on the study day, of whom 14 patients had septic shock. The most 245 
common presumed origin of sepsis was an abdominal cause (70%), followed by a pulmonary cause 246 
(13%).  247 
On the study day, 14 patients had an open abdomen, 56 patients had a stoma and 23 had an 248 
enterocutaneous fistula. 249 
Data on outcome day 250 
90 day outcome data were obtained in 330/338 (98%) patients. For the 8 patients with missing data, 251 
2 did not have AIF and 6 had AIF.  The hospital outcome at 90 days is shown in Table 5.  252 
Table 5. Outcome data at day 90. Data presented as number of patients (percentage) or median [interquartile range] if not 253 
stated otherwise. 254 
 All patients 
N=330 
CIF 
N=49 
AIF 
N=200 
Non-IF 
N=81 
p-value 
AIF vs non-
IF 
Outcome      0.257 
Discharged 239 (72.4) 39 (79.6) 147 (73.5) 53 (65.4)  
Deceased 71 (21.5) 6 (12.2) 41 (20.5) 24 (28.9)  
Still in hospital 20 (6.1) 4 (8.2) 12 (6.0) 4 (4.8)  
Abdominal surgery  196 (59.4) 27 (55.1) 147 (73.5) 22 (27.1) <0.001 
Two or more abdominal 
surgeries 
77 (22.8) 12 (24.5) 57 (28.5) 8 (9.9) 0.001 
Presence of a stoma 
during the study 
110 (33.3) 32 (65.3) 70 (35.0) 8 (9.9) <0.001 
Presence of fistula during 
the study 
58 (17.6) 16 (32.7) 38 (19.0) 4 (4.9) 0.003 
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Total duration of PN, days 19 [10-37] 26 [11-79] 19 [10-37] 17 [10-29] 0.269 
Total patients in the ICU 174 (52,7) 19 (38,8) 118 (59.0) 37 (45.7) 0.014 
Total ICU stay, days 29 [16-50]  27 [16-42] 30 [16-46] 26 [16-75] 0.647 
Total hospital stay, days 36 [21-61] 26 [14-54] 38 [21-61] 35 [23-71] 0.950 
ICU – intensive care unit; IF – intestinal failure; PN – parenteral nutrition; AIF –acute intestinal failure; CIF – chronic 255 
intestinal failure  256 
The total 90-day hospital mortality in patients with PN was 21.5%, and in patients with AIF 20.5%. Of 257 
the patients without IF, 41 patients (77%) were discharged home, 8 patients transferred to another 258 
hospital and 4 patients discharged to a rehabilitation center. Of the patients with AIF, 100 patients 259 
(68%) were discharged home, 29 patients transferred to another hospital, 12 patients to a 260 
rehabilitation center, 3 patients to a hospice and 3 patients to another institution. Of the patients 261 
with CIF, 33 patients (67%) were discharged home, 4 patients to another hospital and 2 patients to a 262 
rehabilitation center.  263 
At 90 days after the study day 5/70 AIF patients, 3/32 CIF patients and 1/8 no IF patients no longer 264 
had a stoma. At 90 days 17/38 AIF patients no longer had a fistula (11 were closed surgically, 6 closed 265 
without surgery). In 6/16 CIF patients with a fistula were successfully treated surgically. Four patients 266 
categorized as no IF on the study day developed a fistula during their hospital stay, in 2/4 the fistula 267 
closed within 90 days, one of these with surgery. In two of these patients “perceived danger from 268 
EN” and in two “no access for EN” was documented as a reason for PN on the study day. 269 
The outcomes (mortality, ICU admission, duration of PN and hospital stay) of AIF patients without 270 
abdominal surgery were not different from surgical patients (data not shown). 271 
Associations of PN and AIF with 90-day hospital outcome 272 
There was a significant association between active sepsis on the study day and the risk of death.  273 
Prolonged PN was also associated with higher mortality, ROC curve analysis identified that a total 274 
duration of PN of ≥42 days as the most informative threshold for hospital mortality within 90 days.  275 
Older patients, those who had an intestinal stoma, and those who had required an ICU stay during 276 
the current admission were also more likely to die (Table 6). 277 
Multivariate analysis yielded the final regression model presented in Table 7.  Age, sepsis on the 278 
study day, ICU admission during the current hospitalization, and duration of PN ≥42 days were 279 
independently associated with 90-day hospital mortality, the strongest of these being for the long 280 
duration of PN, but sepsis and ICU admission were also associated with more than double the risk of 281 
death. 282 
  283 
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Table 6. Comparison of survivors and non-survivors. Data presented as number of patients (percentage) or median 284 
[interquartile range] if not stated otherwise. 285 
 All (330) Survivors 
(N=259) 
Nonsurvivors 
(N=71) 
-value 
Age, median [range] 64 [19-85] 58 [19-85] 69 [25-83] <0.001 
Male gender 166 (50.3) 133 (51.4) 33 (46.5) 0.276 
Home PN before 
hospitalization 
44 (13.3) 38 (14.7) 6 (8.5) 0.119 
IF as the reason for 
PN on study day 
No IF 
AIF 
CIF 
 
 
81 (24.5) 
200 (60.6) 
49 (14.8) 
 
 
57 (22.0) 
159 (61.4) 
43 (16.6) 
 
 
24 (33.8) 
41 (57.7) 
6 (8.5) 
0.056 
Sepsis on study day 66 (20.0) 45 (17.4) 21 (29.6) 0.002 
Number of 
abdominal surgeries 
1 [0-1] 1 [0-1] 1 [0-1] 0.983 
Abdominal surgery 
ever 
196 (59.4) 157 (60.6) 39 (54.9) 0.233 
Stoma ever 110 (33.3) 93 (35.9) 17 (23.9) 0.038 
Fistula ever 58 (17.6) 47 (18.1) 11 (15.5) 0.373 
Total duration of PN 28 [15-65] 30 [15-72] 27 [17-50] 0.130 
PN for >=14 d  209 (63.3) 161 (62.2) 48 (67.6) 0.242 
PN for >=42 d 74 (22.4) 52 (20.1) 22 (31.0) 0.039 
Total ICU days 29 [16-50] 25 [15-44] 33 [18-73] 0.200 
ICU admission ever 174 (52.7) 127 (49.0) 47 (66.2) 0.007 
Total hospital stay, 
days 
36 [21-61] 35 [22-59] 40 [19-78] 0.309 
ICU – intensive care unit; IF – intestinal failure; PN – parenteral nutrition; AIF –acute intestinal failure; CIF – chronic 286 
intestinal failure 287 
Table 7. Stepwise multiple regression analysis identifying variables associated with hospital mortality within 90 days. 288 
Variable P-value Odds ratio 95% CI lower 95% CI 
upper 
Intestinal failure     
No IF 0.988    
Acute IF 0.956 1.053 0.166 6.689 
Chronic IF 0.886 1.107 0.276 4.428 
Age 0.013 1.029 1.006 1.052 
Sepsis on study day 0.024 2.349 1.120 4.925 
Home PN before  0.731 0.775 0.180 3.325 
Stoma ever 0.230 0.624 0.289 1.347 
ICU admission ever 0.023 2.459 1.133 5.336 
3 or more abdominal 
surgeries 
0.105 0.405 0.136 1.206 
PN ≥42 days 0.008 2.868 1.319 6.235 
IF – intestinal failure; PN – parenteral nutrition; CI – confidence interval 289 
DISCUSSION 290 
Our study has estimated the prevalence of PN to be 2.1% in adult patients hospitalized in acute care 291 
hospitals. Acute IF was the main reason for usage of PN (in 61% of patients), and the prevalence of 292 
acute IF in adult patients in acute care hospitals was 1.3%. Patients receiving PN had high hospital 293 
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mortality (20.5%), and a long hospital stay (36 days), whereas outcomes of acute IF patients did not 294 
differ significantly from those in other patients receiving PN. 295 
Our pragmatic study aimed to obtain the very first results on overall prevalence and description of 296 
acute IF to form the basis for future studies. 297 
Prevalence of PN and IF 298 
We did not identify any earlier studies identifying the prevalence of PN in hospitalized patients. Our 299 
study suggests rather low total number of patients receiving PN, although considerable variability 300 
between different countries and institutions exists. This was exemplified by our partial exclusion of 301 
center 10 which has a specialist practice concentrated on patients at high risk of PN and AIF, as 302 
compared to the larger multidisciplinary hospitals that included many acute services (such as 303 
respiratory medicine for example, where AIF would be much less common than in the surgical units 304 
of those hospitals). Our results on prevalence should therefore be interpreted with caution. 305 
Additional small errors may also result from the point-of-prevalence design and because we counted 306 
prevalence for acute care beds instead of the exact number of patients. The precise number of 307 
patients being treated during one day in entire hospitals is difficult to identify due to multiple 308 
discharges and admissions, therefore number of beds was taken into account instead. Furthermore, 309 
the methodology behind this study called only for patients actually treated with PN, although there 310 
must be awareness that the time to initiate parenteral nutrition in comparable conditions may be 311 
different between settings. More precise results would require a prospective observational study 312 
with a relatively long screening period. 313 
The prevalence of acute IF in our study is lower than was estimated by the NHS in the UK (9). The 314 
actual overall prevalence could be even lower taking into account that most hospitals participating in 315 
this study are university hospitals and therefore tertiary referral centers. Moreover, several 316 
participating sites had specialized IF units which are still uncommon worldwide.  317 
This study showed that there was some discrepancy between the opinion of local investigators and 318 
the expert panel for the reasons for PN. Compared to local investigators, the experts categorized 319 
more patients as having acute IF (206 instead of 159). Such discrepancy suggests that the concepts 320 
and definitions of intestinal failure – only very recently reviewed - require further time and 321 
experience so they can be more widely understood and applied (12). 322 
There was a considerable proportion of patients receiving PN without having acute or chronic IF 323 
(Table 3). Of note, these patients often had GI pathology without IF, meaning that ability of the 324 
bowel to absorb was at least thought to be maintained. This group includes patients with GI 325 
pathology resulting in or accompanied by dysphagia or obstruction, and those without established 326 
access for EN (e.g. esophageal pathology) or perceived danger of EN (e.g. pancreatitis, anastomosis). 327 
Respective decisions to administer PN in these cases were taken at each site and not influenced 328 
centrally. 329 
In acute IF patients, whenever possible, treatment of the origin of the condition is of utmost 330 
importance and PN then just provides a “bridge” until restoration of intestinal function. Many 331 
patients with severe illness require IVS with fluids and electrolytes due to increased requirements in 332 
the acute phase which are unrelated to acute IF. At the same time, acute intestinal insufficiency is 333 
initially managed with trophic enteral nutrition without supplementary PN, as in other severely ill 334 
patients (2). 335 
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Mechanisms of acute IF 336 
Disordered motility was considered to be the mechanism of acute IF in more than half of the cases 337 
(Table 3). It should be noted that this categorization does not imply that these patients were 338 
considered to have an underlying chronic motility disorder (primary dysmotility). Identification of the 339 
pathophysiological mechanism leading to AIF as well as identification of this acute dysmotility was 340 
difficult; in more than 10% of cases ‘other’ pathophysiological mechanisms were documented (Table 341 
4), and expert review of collected data did not always allow clear categorization into predefined 342 
groups either. The main reason for this is the lack of appropriate objective tools to identify the 343 
presence of dysmotility or of progression to gastrointestinal mucosal injury. Development of 344 
diagnostic markers to identify both intestinal dysmotility and mucosal injury at the bedside is 345 
required.  346 
The most frequently documented underlying disease causing development of acute IF was a surgical 347 
complication followed by active malignancy, in line with previous results from Lal et al. (13).  Most of 348 
the patients with acute IF were abdominal surgery patients (73.5% underwent abdominal surgery, 349 
13.1% of them twice, and 27.7% more than twice during the index hospitalization). In a recent study 350 
addressing patients with AIF, the median number of surgeries per patient was as high as four (8). 351 
Possibly only the most complicated surgical patients were identified in this previous study, supported 352 
by the fact that two thirds of patients had fistula(s) (8). In our study, we will also have captured less 353 
complicated surgical patients (including Type I IF).  354 
However, a quarter of patients in our study had not undergone surgery and still developed AIF with 355 
outcomes comparable to patients undergoing abdominal surgery. These patients may be the most 356 
challenging subgroup of patients, as AIF in these cases is usually not caused by anatomical 357 
abnormalities (short bowel, fistula), but is purely functional. Laboratory or other markers to identify 358 
disordered intestinal function and subsequent insufficient absorption of nutrients in anatomically 359 
intact bowel would be useful indicators for future studies (14). 360 
Outcome 361 
The mortality of patients with AIF in this study was 20.5%, whereas Atema et al. (8) reported hospital 362 
mortality of AIF patients to be 16%. Patients in the above-mentioned study were referred to an IF 363 
specialized center and had already been on PN for a median of 2 months before referral. Our current 364 
study, in contrast, could also identify patients in the early phase of acute IF. One third of our AIF 365 
patients were in the ICU on the study day and two thirds needed intensive care during their hospital 366 
stay, whereas only 23% of patients in the study by Atema et al had an unplanned admission to ICU 367 
postoperatively. These differences need to be taken into account when interpreting mortality. 368 
However, we believe that referral of patients with Type II IF to a specialized center should be a 369 
standard strategy and can improve survival. The mortality in established IF units is estimated to have 370 
fallen from over 10% in the 1980s to less than 5% in the last 10 years (unpublished data from Salford 371 
and St Marks hospitals, UK). 372 
 373 
Sepsis is undoubtedly an important component in the course of acute IF leading to impaired 374 
outcome. In current study, presence of sepsis on the study day was associated with increased 375 
hospital mortality. This is important, as it is the only one of the four risk factors identified by 376 
multivariate analysis, which is directly amenable to intervention - either by better treatment or by 377 
anticipation and prevention. However, the point-of-prevalence design does not allow more detailed 378 
interpretation of the role of sepsis with our data. 379 
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Other variables associated with 90-day hospital mortality in patients receiving PN were age and 380 
admission to ICU during the current hospitalization. Duration of PN as a continuous variable did not 381 
add to prediction of mortality, whereas PN ≥42 days as a categorical variable based on a cut-off 382 
identified with current data did. Whether this cut-off may add to a future definition needs to be 383 
clarified. However, possible previously proposed empiric cut-offs for defining acute IF such as 28 days 384 
(8) did not allow the identification of patients with impaired survival, and a definition that can be 385 
realized only after 42 days is of limited clinical value. 386 
Other patient outcomes beyond hospital stay were not assessed in our study. Earlier studies in 387 
chronic IF patients have demonstrated that home PN is associated with sarcopenia (6) and 388 
osteoporosis (7). 389 
Due to the above-mentioned limitations of our study design, our final model of multiple regression 390 
analysis serves as a basis for future studies and cannot itself be interpreted as an identification of risk 391 
factors for mortality in patients on PN. 392 
 393 
Strengths and limitations 394 
The main strength of our study is that it is the first study to screen all adult hospitalized patients 395 
receiving PN to identify the overall prevalence of acute IF. A multicenter worldwide design adds to 396 
the achievement of representative results. 397 
Limitations, as already discussed above, include the point-of-prevalence design, that the number of 398 
acute care beds was used to describe prevalence and that 90 day outcome was limited to data 399 
available in the hospital. However, considering a long hospital stay among study patients, the 400 
expected number of patients where death might have occurred after discharge from the hospital but 401 
within 90 days of study day is low. All these limitations were foreseen but unavoidable in this 402 
pragmatic study. 403 
An additional limitation to the interpretation of our results is the difficulty in identifying acute IF. 404 
However, our study can be seen as the first step towards improvement in this regard.  405 
 406 
Conclusions 407 
In this point-of-prevalence study, 21 patients per 1000 adult acute care beds received PN, and in 408 
more than half of them (13 patients/1000 beds) the reason for PN was acute IF. The majority of 409 
patients (68%) categorized to have acute IF had previously undergone abdominal surgery and the 410 
main mechanism of AIF was an acute motility issue. Patients receiving PN had high 90-day hospital 411 
mortality, whereas the presence of AIF did not additionally influence this outcome. Patients who had 412 
sepsis on the study day, those of older age and those who were admitted to ICU had significantly 413 
higher mortality. The duration of PN most associated with increased 90-day hospital mortality in this 414 
study was 42 days or longer. All four factors were independently associated with 90-day hospital 415 
mortality. 416 
 417 
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